中华心血管病杂志
2014年 · 第42卷第06期
中华心血管病杂志
- 全部
- 总编随笔
- 专题笔谈
- 肺高血压
- 临床研究
- 基础研究
- 流行学与人群防治
- 病例报告
- 病理报告
- 指南解读
- 学术争鸣
- 综述
After the publication of the American College of Cardiology (ACC) /American Heart Association (AHA) 2013 Guidelines for the Treatment of Blood Cholesterol to Reduce the Risk of Atherosclerotic Cardiovascular Disease in Adults (the "New Guidelines"), it caused widespread controversy. Relevant academic institutions and experts in China have also discussed and questioned the "new guidelines", and their opinions are basically consistent. The "new guidelines" are not applicable to clinical practice in China.
This short review illustrates current epidemiology, diagnosis and treatment of pulmonary hypertension. In the first part, classification, definition and prevalence of pulmonary hypertension (PH) are explained. According to recent reports, overall PH prevalence was 0.3% to 6.0% with left heart disease occupying the most proportion, followed by pulmonary disease, pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) constituting far less proportion of 10 to 50 per 1 million people. In diagnosis, flow of diagnosis of PH, differential diagnosis of PH and how to determine the severity of PH are explained including recent development of magnetic resonance imaging (MRI) and gene abnormality study on BMPRⅡ. In treatment, newly–developed pulmonary vasodilators are shown as well as how to combine them in PAH, and in CTEPH treatment the drugs, operation and catheter therapy including our experience are demonstrated.
Epidemiologic patterns of pulmonary arterial hypertension differ by era and region and may shed light on the pathophysiology and treatment of the disease. New efforts to target one or more of the recently studied therapies could establish personalized medicine as standard care in pulmonary arterial hypertension.
Clinical guideline for treatment of pulmonary arterial hypertension (PAH) has been changing during the past 10 years with development of targeted therapy for PAH. Treatment of PAH should include general measures and supportive care, treatment of associated disease, targeted treatment for PAH, and lung transplantation in advanced cases. Targeted therapy for PAH can improve symptom, quality of life and time to clinical worsening in PAH patients. Regular follow–up to evaluate the treatment efficacy is essential and insufficient treatment efficacy should be modified with other class of medication or preparing lung transplantations. Research for new medication is actively performed and novel drug is expected to be improving survival of PAH patients.
pulmonary hypertension due to left heart disease (LHD – PH) is caused by left heart disease and is one of the common types of pulmonary hypertension. In the current European, US and Chinese guidelines for pulmonary hypertension, LHD – PH is classified as the second largest category[
Hereditary pulmonary hypertension is a kind of malignant pulmonary vascular disease characterized by pulmonary arteriolar remodeling, which causes progressive increase of pulmonary artery pressure and pulmonary vascular resistance and ultimately leads to right heart failure and death. The natural prognosis is extremely poor, with a median survival time from diagnosis to death of only 2.8 years and less than 10 months in pediatric patients[
The patient was an 80-year-old female who was admitted to the hospital on 25-Jun-2013 due to chest pain for 6 h. The patient was admitted to the hospital with persistent chest pain, pale complexion and sweating profusely. Physical examination revealed that the patient had a blood pressure of 88/62 mmHg (1 mmHg =0.133 kPa), a heart rate of 62 beats/min, and no dry or wet rales were heard in either lung. ECG showed ST segment elevation 0.15~0.2 mV in leads Ⅱ, Ⅲ and aVF, V3R~ V5RThe ST segment elevation of the lead was 0.1 mV, and "acute inferior wall and right ventricular myocardial infarction" was considered. Aspirin tablets 300 mg chewed and clopidogrel 300 mg orally were given, and appropriate fluid rehydration and dopamine booster treatment were given. He had a history of hypertension for 10 years, and the highest blood pressure was 180/112 mmHg. He was usually treated with perindopril tablets + amlodipine tablets, and his blood pressure was controlled. Another patient had a history of atrial fibrillation for 5 years, and he was usually not treated with antithrombotic drugs. Emergency coronary angiography showed no obvious abnormalities in the left main trunk, anterior descending artery and circumflex artery, blood flow TIMI grade 3, right coronary artery was thick, posterior trigeminal anterior occlusion, blood flow TIMI grade 1, and a large number of thrombosis were seen (
Diabetes is an important public health problem in Europe and globally. Some 52 million people in Europe had diabetes in 2011, rising to 64 million in 2030, and half the population is unaware they have it. In addition, a large number of people are in a state of prediabetes. Diabetic patients have an increased risk of cardiovascular disease, and more than 60% of diabetic patients suffer from and eventually die from cardiovascular disease. Screening for diabetes in healthy people, cardiovascular risk assessment in diabetic patients, early diagnosis and active intervention are important strategies to reduce the burden of disease and reduce fatal and disabling events.
There are many opinions on the significance of "decreasing" and "reaching the standard" of low density lipoprotein cholesterol (LDL-C) in lipid-lowering treatment. For example, LDL-C should be reduced as low as possible, or a little lower is better, etc. Specific LDL-C should be reduced to the standard value, in low-risk groups is<4.14 mmol/L (160 mg/dl), Intermediate risk population<3.37 mmol/L (130 mg/dl), High-risk population<2.59 mmol/L (100 mg/dl), Very high-risk population<1.80 or 2.07 mmol/L (70 or 80 mg/dl). All the above statements have some basis. In short, it is the mainstream understanding in today's medical field that lipid regulation must meet the standard.
Syncope is a transient loss of consciousness caused by transient global brain ischemia, often accompanied by loss of autonomic muscle tone, with the characteristics of rapid onset, transient, self-limiting and complete recovery[
本期目次

